Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
IT0004147952
Wed, 04.10.2023
Newron Pharmaceuticals S.p.A.
Newron to present three posters on its clinical program evaluating evenamide in the treatment of schizophrenia at the 36th European College of Neuropsychopharmacology Congress
Poster presentations will include the full results from all 161 patients randomized in study 014 at the six-month time point from extension study 015, a Phase II trial evalu [ … ]
Mon, 02.10.2023
Newron Pharmaceuticals S.p.A.
Newron appoints Margarita Chavez as board advisor
Margarita Chavez, former Managing Director at AbbVie Ventures, to be nominated for election to the Board of Directors at the Ordinary AGM 2024
Milan, Italy, October 2, 2023 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development [ … ]
Fri, 04.08.2023
Newron Pharmaceuticals S.p.A.
Newron announces H1 2023 results and provides R&D update
Milan, Italy, August 4, 2023, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial resul [ … ]
Mon, 15.05.2023
Newron Pharmaceuticals S.p.A.
Newron presents exciting new data from study 014/015 at
CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
Study 014/015 is a Phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS)
Full data from first 100 patient [ … ]
Mon, 15.05.2023
Newron Pharmaceuticals S.p.A.
Newron presents exciting new data from study 014/015 at
CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
Study 014/015 is a Phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS)
Full data from first 100 patient [ … ]
Wed, 03.05.2023
Newron Pharmaceuticals S.p.A.
Newron to present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
Further data from study 014/015 of evenamide in treatment-resistant schizophrenia (TRS) confirms potentially relevant role of glutamatergic release modification when added to TRS patients no [ … ]
Wed, 03.05.2023
Newron Pharmaceuticals S.p.A.
Newron to present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
Further data from study 014/015 of evenamide in treatment-resistant schizophrenia (TRS) confirms potentially relevant role of glutamatergic release modification when added to TRS patients no [ … ]
Tue, 02.05.2023
Newron Pharmaceuticals S.p.A.
Newron announces Senior Management Team changes
Milan, Italy, May 2, 2023, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that the Board of Directors has a [ … ]
Tue, 02.05.2023
Newron Pharmaceuticals S.p.A.
Newron announces Senior Management Team changes
Milan, Italy, May 2, 2023, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that the Board of Directors has a [ … ]
Tue, 18.04.2023
Newron Pharmaceuticals S.p.A.
Newron announces AGM 2023 results
Milan, Italy, April 18, 2023 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), announces that its shareholders approved all motions on the age [ … ]